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Acute Hemodynan:-1c Effects of FK 506 During and After Orthotopic 
Liver Transplantation 
Y. Kang, M.A. Mazer, A.M. DeWolf, J.J. Fung, T. Gasior, R Venkataramanan, and T.E. Starzl 
. , THE introduction of Cya was a ml\ior breakthrough in 
organ transplantation. However. side effects of the 
drug. such as frequent episodes of re~tionI nephrotoxic-
ity, and hypertension, stimula~a I~h for agents 
devoid of such effects. A recently4eve1Oped drug, FK 506, 
appears to be superior to Cy A in immuOOsuppression, with 
an advantage in humans of .mlniniaJ side effects. I Its 
reported effects on the cardiovascular systein are variable, 
ranging from no organic change2-4 to vasculitis and myo-
cardial necrosis.' The organic. chMges seen in animal" 
studies may have been species specific; 
This study was designed to investigate the acute hemo-
dynamic effects of FK 506 in patients receiving a large 
loading dose followed by a maintenance dose. 
MATERIALS AND METHODS 
This study was approved by the Institutional Research Review 
Board, and informed consent was obtaiMdfl.om the patients. 
Sixteen adult patients undergoing primary Orthotopic liver t{allS' 
plantation were studied. Anesthetic manaaement followed the 
standard care at Presbyterian-University Hospital (Pittsburgh, 
PA). Anesthesia was induced with thiopental and maintained with 
-isoflurane and fentanyl. Electrocanliograms (ECGs) were cOntin-
uously recorded by a data acquisition system,'Complete hemody-
namic profile and biochemical variables, including arterial blood 
gas tensions, electrolytes. ionized calcium, glucose. and lactate. 
were measured. In addition. right ventric~ ejection fraction ~as 
measured with a REF-ejection fraction/cardiac ou(put computer 
(Baxter, Irvine, CAl. Standard surgical procedure was followed, 
including the use of vena-venous bypassIMethylpn~anisolone (I 
g) was given after reperfusion of the grafted liver. During biliary . 
reconstruction. a loading dose of FK S06 (0.15 mgIkg) was infused 
over 1 bour. This was the first dose ofintravenous FK S06 given, 
as well as the largest. Postoperatively, maintenance doses of FK 
506 (0.075 mg/kg) were administered over I hour, every 12 hours. 
Intraoperatively, a complete bemodynamic profile and set of 
biochemical measurements were obtained S mirtutes and I minute 
before, and IS minutes (FK + lpF"PM~utes (FK + 30), ., 
minutes (FK + 45). 60 minutes (FK + 60), 90 minutes (FK. + 90), 
and 120 minutes (F'K. + 120) after~ start of die fitst FK 506 
infusion. Postopenllively, a bemodynaniic profile was measured 
paior K~Ktnd iuuDediately after a, mairite~ dose of FK ~ 
infyrpiln:<~tK" ,-,_:-"" ~K-I .-. <,-:-;--_ .. /<1,;-\.:m:,+< __ /D-~lD • ''"l'<o':'. 
.' Data are piesentcd as mean ::t: SiiTbey were analyzed by 
analysis of variance, and specific difference were assessed using 
the Student-Knewman-Keuls test. A value of P < 0.05 was 
consideied statistic:aDy significant.' . 
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"RESUlts 
The average age of re<;ipients was 37.7 ± 13.9 years, and 
DO patient requiml vasopressor support other than a small 
dose of dopamine (:5 2 J.I8 kg-I min-I) given to 12 patients 
to improve renal perfusion. 
Intraoperative Loading Dose 
In three patients. data were available only up to 90 minutes 
alttr the start of FK 506 infusion because th,\operation 
had ended by that time. The only biochemical changes 
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Table 1. Bklcttemlcal Proflle e8rore, During, a_nd After AdminIstration of a loading Dos8 of FK ~ (0.15 mg' kg-1). 
Before 
f1( 508 . FK + 15 A<+80 FK + 120 
pH 7.37:t 0.04 7.39:t 0.03 7.40:t 0.05 7.41 ± 0.05' 
pCOa (mmHg) 39± S 38:t 4 37:t 3 36:t 3' 
pOa (mmHg) 270 ± 44 266 ± 39 248 ± 48 231 ± 61' 
Base excess (nvnoI'l-') -2.8 ± ~KT -1.9 ± 2.0 ~1KS ± 3.2 -1.S± 3.3 
Na (mmol . l-') 137 ± 5 139 ±4 139±5 139 ± 5 
K (mmol . l-') 3.5 ± 0.5 3.4 ± 0.4 3.5 ± 0.4 3.5 ± 0.4 
ca++ (mmol'l-') 1.07 ± 0.11 1.04 ± 0.11 1.00 ± 0.09 1.00 ± 0.10 
Glucose (mg . d1-') 204± 47 210 ± eo 229±73" 226 ± 63 
lacIate (mmol 'l-') 5.8 ± 2.4 5.6 ± 2.5 5.0± 2.8 5.1 ± 2.7 . 
Note: Values BIt mean ± SO. 
, P < 0.05 ~ with baseline values. 
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Table 2. Hemoc:IynIImIc ProfIle 8efor., Durtng. .rid After Admlnlstraion of. loading 00.. of fI( 506 (0.15 mg • kg-,) 
." - . - . -
EleIoni. 
! 
. _ ~ - -,n.;' ~ ~~-K;K;~K~--~ 
" 
. FKtsOe ~-KD": . I~ '" • FK + 15 FK. + 30 "~:~D-K FK+ eo D~~~D~~"Df . fI( + 120 
MAP ni10 ni:8 n:J:9 76:J:9 78:J: 11 
HR. ge ~ 14 93 ± 13 92:J: 13 K~ • .,r;' -f 93 ± 14 93± 15 
MPAP "19±4 18:t ~K 18 % 4 19:1:4 20:1:4 RvsP 36i7 37:1: 10 35 :tl "35:t10 37:1:8 
RVDP 8±5 9:t5 8%5 ~ 9±5 9:1:5 
PCWP 10±4 . 11 :t 4 11:1: 3 i- 11 :J: 3 11 :J: 2 
CvP 10 % 4 . 10± 4 10±4 10 ±3 11 ± 3 
CI 4.5:1: 1.4 4.4:t 1.5 4.3:1:1.4 .... ±1.5 3.9 ± 1.5 
SVI 48:1:18 48± 18 47:J: 15 
' .... :':. 48 ± 18 43 ± 18 
RVEF 50 % 8 48±11 48±9 4s ± 10 48:J: 1.0 
LVSWl 43:J: 1~ 43± 18 42± 1~ DK>~ 42 ± 15 39:J: 18 
RVsW. U~P .' K~±4 5:J:3 6 % 2. . -~ 5±3 
SVAI . 1317 ± S39 1368 ± 51'4 . 1376 ± 444 1337 ± 485 1580 ± 704 
PVRI 167 ± 95 163:J: 101 155 ± 104 179 ± 114 229 ± 201 
BT 34.3 % 1.0 34.4:J: 1.1 34:·4:J: 1.1 34.4:J: 1.2 34.5 ± 1.2 
NoIe: ValUos are mean ± SO. ~ profiles remained unchanged !bing !he observation period. ' . . 
Abbreviations: MAP (mml-/g).1TIM'I arterial pressure; HA (beat • mIn-'). heart rate; MPAP (mrnHg). rne8n putnonaty artery presstn; RVSP (1\'lI11Hg). rtgM ventricIAar 
Systol"oc pressure; RVOP (nvnHg). ~ ventricular diastolic pressure; PCW? (nvnHg). JlI*nona'y capIIary wedge pressu-e; CV? E~FK ceqtral venous pressure; CI 
(l' mIn-' . m-'l; cardiac Index; SVI (mi' m--,. ~troke volume Index; RVEF (%). right ventricular ejectionfracllon; LVSWI (g' m' m--,.Ieft venIrt<:Uar s1roke WOIk Index; 
RVSWI (g' !!'I' m-,). right ventlcU8r strOke \¥OIl( Index; SVRI (dynes' eec' em-I. m-'l. systemic ¥lI9CIMr resIsIance Index; PVR! (dynes' sec' em-I. m-'), 
pUmonary vascufar resIs1ance Index; and BT ("C). body temperature. 
observed duiini the study period were a minimal increase 
in pH and decreases in pCOz and pOl seen 120 minut~s 
after the FK 506 iilfusion. Other variables remained un-
changed and they were all within the normal range for this 
patient pOpulation (Table I). No supraventricular or ven-
tricular dysrhythmia was observed on the ECG record-
ings. Measured hemodynamic variables showed no signif-
icant change during the 2-hour period (Table 2). 
Table 3. Hemodynamic Proflle Before and After a Maintenance 
Dose of FK S06 (0.075 mg . kg-') 
Variables Before Aller 
MAP 95: 17 97: 18 
HR 100 ± 13 101 :I: 11 
MPAP 19:J: 6 19 ± 5 
PCWP 12 ± 5 10 ± 5 
CVP 9±3 8:1:3 
CI 5.4 ± 1.0 5.3: 0.9 
SVI 54.9 ± 14.5 53.2 ± 11.9 
LVSWI 62.3 ± 20.9 62.2 ± 15.7 
RVSWI 7.S:J: 2.9 7.7 ± 2.8 
SVRI 1340 ± 400 13n ± 338 
PVRI 109 ± 50 120:1: 87 
BT 36.8 ± 0.8 36.8 ± 0.5 
NoIe: Values are mean :!: SO. Hemodynamic profile remalned unchanged 
during the obseIvation period. See Table 2 for definitions of abbreviatlona. 
Postoperative Maintenance Dose 
No dysrhythmia was aSsociated with FK 506 administra-
tion. The hemodynamic profile was similar before and 
after infusion of FK 506 (fable 3). 
DISCUSSION 
The results indicate that infusion of FK 506. both a large 
loading dose given during surgery and a maintenance dose 
given during the postoperative period, is not associated 
with acute cardiovascular effects or hemodynamic com-
promise. Bolstered by these negative results. this new drug 
has been used in four heart recipients and in one heartnung 
recipient without clinically significant side effects. Further 
studies are needed to evaluate chronic effects of FK 506 in 
organ transplantation recipients. 
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